Published in Gastroenterology on June 02, 2010
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology (2011) 8.95
IL28B and the control of hepatitis C virus infection. Gastroenterology (2010) 3.02
IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. J Exp Med (2013) 2.24
Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS One (2011) 1.69
An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver. Can J Gastroenterol (2012) 1.57
Spontaneous clearance of hepatitis C virus in vertically infected children. Eur J Pediatr (2011) 1.47
IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS One (2011) 1.39
Interferon lambdas: the next cytokine storm. Gut (2011) 1.25
Genetics of IL28B and HCV--response to infection and treatment. Nat Rev Gastroenterol Hepatol (2012) 1.20
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2016) 1.15
Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology (2011) 1.10
IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association. J Infect Dis (2011) 1.07
Interferon lambda: a new sword in cancer immunotherapy. Clin Dev Immunol (2011) 1.04
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther (2013) 1.03
Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis (2011) 1.02
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica (2011) 1.00
Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr (2011) 0.99
KASL clinical practice guidelines: management of hepatitis C. Clin Mol Hepatol (2014) 0.99
APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int (2016) 0.96
IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon (2011) 0.96
Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS One (2012) 0.94
Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS One (2012) 0.93
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol (2011) 0.91
Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India. J Clin Exp Hepatol (2014) 0.90
Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa. Int J Nanomedicine (2014) 0.89
Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents. Hepat Med (2014) 0.89
Baseline and Dynamic Expression of Activating NK Cell Receptors in the Control of Chronic Viral Infections: The Paradigm of HIV-1 and HCV. Front Immunol (2014) 0.89
Impact of Il28b-related single nucleotide polymorphisms on liver transient elastography in chronic hepatitis C infection. PLoS One (2013) 0.89
Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients. World J Gastroenterol (2013) 0.88
IL-28B polymorphisms and the response to antiviral therapy in HCV genotype 2 and 3 varies by ethnicity: a meta-analysis. J Viral Hepat (2013) 0.88
Progression of liver fibrosis in HIV/HCV genotype 1 co-infected patients is related to the T allele of the rs12979860 polymorphism of the IL28B gene. Eur J Med Res (2011) 0.88
The Correlation of Il28B Genotype With Sustained Virologic Response In Romanian patients With Chronic Hepatitis C. Hepat Mon (2011) 0.88
Host factors determining the efficacy of hepatitis C treatment. J Gastroenterol (2012) 0.88
The IFN-λ Genetic Polymorphism Association With the Viral Clearance Induced by Hepatitis C Virus Treatment in Pakistani Patients. Hepat Mon (2014) 0.86
Predictive factors associated with hepatitis C antiviral therapy response. World J Hepatol (2015) 0.86
IL-28B As a Predictor of Sustained Virologic Response in Patients with Chronic Hepatitis C Virus Infection. Gastroenterol Hepatol (N Y) (2011) 0.86
The association of IL28B genotype with the histological features of chronic hepatitis C is HCV genotype dependent. Int J Mol Sci (2014) 0.85
The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Transl Med (2012) 0.85
Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Med (2012) 0.84
Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection. Biomed Res Int (2014) 0.83
CD4saurus Rex &HIVelociraptor vs. development of clinically useful immunological markers: a Jurassic tale of frozen evolution. J Transl Med (2011) 0.83
Interleukin-28B genotype testing to determine response to the combination of pegylated-interferon and ribavirin for the treatment of hepatitis C virus. PLoS Curr (2011) 0.82
Virological predictors of response to retreatment in hepatitis C genotype 2 infected patients. PLoS One (2013) 0.82
Host genetic variants in the pathogenesis of hepatitis C. Viruses (2012) 0.82
Challenges in Providing Treatment and Care for Viral Hepatitis among Individuals Co-Infected with HIV in Resource-Limited Settings. AIDS Res Treat (2012) 0.82
Interleukin-28 and hepatitis C virus genotype-4: treatment-induced clearance and liver fibrosis. World J Gastroenterol (2012) 0.82
IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am (2012) 0.81
Neopterin as a marker of response to antiviral therapy in hepatitis C virus patients. Hepat Res Treat (2012) 0.81
Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C in different racial populations: A meta-analysis. Exp Ther Med (2011) 0.81
The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C. Clin Dev Immunol (2012) 0.81
IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test. Immunogenetics (2013) 0.80
Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial. Sci Rep (2015) 0.80
IL-28B polymorphisms correlated with treatment response in HCV-4 mono-infected patients: a meta-analysis. PLoS One (2014) 0.80
Comparison of Three Different Methods for Detection of IL28 rs12979860 Polymorphisms as a Predictor of Treatment Outcome in Patients with Hepatitis C Virus. Osong Public Health Res Perspect (2015) 0.78
SNP rs8099917 in gene IL28B might be associated with risk of chronic infection by HCV but not with response to treatment. Biomed Res Int (2014) 0.78
Pretreatment serum interleukin-12 levels in predicting sustained virological response among hepatitis C patients following Pegylated Interferon-α2β plus Ribavirin treatment. Ann Gastroenterol (2013) 0.78
IFNL4 and IFNL3 associated polymorphisms strongly influence the spontaneous IFN-alpha receptor-1 expression in HCV-infected patients. PLoS One (2015) 0.78
Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting. PLoS One (2015) 0.78
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. PLoS One (2014) 0.78
IL28B favorable genotype and ultrarapid viral response as the earliest treatment predictors of a sustained viral response in a Georgian cohort infected with the hepatitis C genotype 1. Eur J Gastroenterol Hepatol (2012) 0.78
Cirrhosis and rapid virological response to peginterferon plus ribavirin determine treatment outcome in HCV-1 IL28B rs12979860 CC patients. Biomed Res Int (2013) 0.78
Individualization of chronic hepatitis C treatment according to the host characteristics. World J Gastroenterol (2014) 0.78
Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Family Community Med (2013) 0.78
IFN-Alpha receptor-1 upregulation in PBMC from HCV naïve patients carrying cc genotype. possible role of IFN-lambda. PLoS One (2014) 0.78
None of the six SNPs of IL28B could predict treatment responses in genotype 2 chronic HCV infected patients by propensity score matching analysis. PLoS One (2012) 0.78
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. Springerplus (2016) 0.77
Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response. BMC Res Notes (2011) 0.77
Distribution of IL-28B genotypes in patients with hepatitis C and healthy individuals in Jahrom city. Gastroenterol Hepatol Bed Bench (2015) 0.77
Polymorphism Near the Interleukin-28B Gene and Anti-Hepatitis C Viral Response. J Clin Transl Hepatol (2013) 0.77
Pre-treatment prediction of response to peginterferon plus ribavirin in chronic hepatitis C genotype 3. World J Hepatol (2015) 0.76
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. Sci Rep (2015) 0.76
The impact of host factors on management of hepatitis C virus. Hepat Mon (2012) 0.76
Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C. World J Gastroenterol (2015) 0.75
PharmGKB summary: peginterferon-α pathway. Pharmacogenet Genomics (2015) 0.75
Polymorphism of IL-28B Gene (rs12979860) in HCV Genotype 1Patients Treated by Pegylated Interferon and Ribavirin. Iran J Pathol (2016) 0.75
Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort. J Viral Hepat (2015) 0.75
Hepatitis C in Argentina: epidemiology and treatment. Hepat Med (2014) 0.75
Interaction of IFNL3 with insulin resistance, steatosis and lipid metabolism in chronic hepatitis C virus infection. World J Gastroenterol (2013) 0.75
Clinical utility of pharmacogenomics in the management of hepatitis C. Pharmgenomics Pers Med (2014) 0.75
Prevalence of interleukin-28B single nucleotide polymorphism genotypes in patients with hepatitis C infection in Isfahan, Iran. Adv Biomed Res (2016) 0.75
Hepatitis C virus pharmacogenomics in Latin American populations: implications in the era of direct-acting antivirals. Pharmgenomics Pers Med (2017) 0.75
Innate immunity: a new chapter for hepatitis C. Ann Gastroenterol (2012) 0.75
Inducible protein-10 as a predictive marker of antiviral hepatitis C treatment: A systematic review. World J Hepatol (2017) 0.75
Distribution of IL28B Polymorphism in a Cohort of Italians and Immigrants with HCV Infection: Association with Viraemia, Stage of Fibrosis and Response to Treatment. J Immigr Minor Health (2016) 0.75
Finding the missing heritability of complex diseases. Nature (2009) 67.95
Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet (2008) 30.94
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature (2009) 26.47
Large recurrent microdeletions associated with schizophrenia. Nature (2008) 20.25
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Rare variants create synthetic genome-wide associations. PLoS Biol (2010) 14.43
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Common variants conferring risk of schizophrenia. Nature (2009) 10.37
Treatment of HCV infection by targeting microRNA. N Engl J Med (2013) 9.91
Uncovering the roles of rare variants in common disease through whole-genome sequencing. Nat Rev Genet (2010) 9.53
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med (2014) 9.45
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med (2014) 8.13
Discerning the ancestry of European Americans in genetic association studies. PLoS Genet (2007) 7.81
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med (2014) 7.73
De novo mutations in epileptic encephalopathies. Nature (2013) 7.42
WGAViewer: software for genomic annotation of whole genome association studies. Genome Res (2008) 7.15
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet (2012) 6.93
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Genome-wide transcript profiles in aging and calorically restricted Drosophila melanogaster. Curr Biol (2002) 5.58
Genic intolerance to functional variation and the interpretation of personal genomes. PLoS Genet (2013) 5.58
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol (2008) 5.08
A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet (2009) 5.01
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med (2005) 4.79
ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature (2010) 4.64
Selection and evaluation of tagging SNPs in the neuronal-sodium-channel gene SCN1A: implications for linkage-disequilibrium gene mapping. Am J Hum Genet (2003) 4.58
Whole-genome sequencing of a single proband together with linkage analysis identifies a Mendelian disease gene. PLoS Genet (2010) 4.29
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med (2014) 4.09
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med (2011) 3.93
Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A (2010) 3.78
The characterization of twenty sequenced human genomes. PLoS Genet (2010) 3.72
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology (2010) 3.57
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med (2003) 3.37
Clinical application of exome sequencing in undiagnosed genetic conditions. J Med Genet (2012) 3.33
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med (2015) 3.16
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med (2015) 3.13
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med (2015) 3.13
Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology (2013) 3.06
Long-range LD can confound genome scans in admixed populations. Am J Hum Genet (2008) 3.06
Hepatitis C pharmacogenetics: state of the art in 2010. Hepatology (2011) 2.99
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
Host determinants of HIV-1 control in African Americans. J Infect Dis (2010) 2.90
Multicentre search for genetic susceptibility loci in sporadic epilepsy syndrome and seizure types: a case-control study. Lancet Neurol (2007) 2.88
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol (2011) 2.84
Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology (2010) 2.83
A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology (2010) 2.78
Priorities and standards in pharmacogenetic research. Nat Genet (2005) 2.65
Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology (2003) 2.64
Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet (2010) 2.61